Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Testing effectiveness (Phase 2)Looking for participantsNCT06970119
What this trial is testing

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd 55
Not applicableStudy completedNCT06809426
What this trial is testing

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

Who this might be right for
PSMA PET-Positive Castration-Resistant Prostate Cancer
Affiliated Hospital of Jiangnan University 13
Very early researchLooking for participantsNCT07798778
What this trial is testing

Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Affiliated Hospital of Jiangnan University 18
Early research (Phase 1)Looking for participantsNCT07641049
What this trial is testing

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate CancerAdvanced Prostate AdenocarcinomaPSCA-positive Prostate Cancer+1 more
Beijing Biotech 36
Large-scale testing (Phase 3)Looking for participantsNCT06855277
What this trial is testing

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 940
Large-scale testing (Phase 3)Looking for participantsNCT06520345
What this trial is testing

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited 520
Large-scale testing (Phase 3)Study completedNCT03511664
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Endocyte 861
Testing effectiveness (Phase 2)Study completedNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 94
Large-scale testing (Phase 3)Looking for participantsNCT07611110
What this trial is testing

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 670
Early research (Phase 1)Looking for participantsNCT07660211
What this trial is testing

Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC）

Who this might be right for
PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VitsGen Therapeutics Inc. 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT06402331
What this trial is testing

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Fusion Pharmaceuticals Inc. 110
Testing effectiveness (Phase 2)Study completedNCT05670106
What this trial is testing

Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 62
Large-scale testing (Phase 3)Not Yet RecruitingNCT07795268
What this trial is testing

Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
Norroy Bioscience Co., LTD 600
Not applicableTemporarily Not AvailableNCT06033001
What this trial is testing

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Castration-Resistant Prostatic Cancer
Lantheus Medical Imaging
Testing effectiveness (Phase 2)Looking for participantsNCT07567521
What this trial is testing

TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
C Ray Therapeutics 90
Early research (Phase 1)UnknownNCT06237491
What this trial is testing

The Safety and Dosimetry Study of 177Lu-LNC1003 Injection

Who this might be right for
Metastatic Castration-resistant Prostate Cancer, mCRPC
Yantai LNC Biotechnology Singapore PTE. LTD. 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT05658003
What this trial is testing

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 63
Testing effectiveness (Phase 2)Looking for participantsNCT07226986
What this trial is testing

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Who this might be right for
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals 123
Large-scale testing (Phase 3)Looking for participantsNCT06780670
What this trial is testing

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 443
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07310355
What this trial is testing

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Chengdu StarRay Therapeutics Co., Ltd 49
Next Page